Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04604210 · ClinicalTrials.gov registry record · Phase 2
Symptom-specific TMS Targets for Depression and Anxiety
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT04604210 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 40 participants.
The verdict
NCT04604210, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This pilot study aims to compare two different treatment targets for transcranial magnetic stimulation, an FDA-approved treatment for major depressive disorder (MDD), in terms of their relative efficacy for depression versus anxiety.
Interventions
- PROCEDURE Transcranial magnetic stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2023-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04604210
The ClinicalTrials.gov registry entry for NCT04604210 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Transcranial magnetic stimulation is the first listed.
NCT04604210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04604210 about?
NCT04604210 is a clinical study titled "Symptom-specific TMS Targets for Depression and Anxiety". This pilot study aims to compare two different treatment targets for transcranial magnetic stimulation, an FDA-approved treatment for major depressive disorder (MDD), in terms of their relative efficacy for depression versus anxiety.
What is the current status of trial NCT04604210?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-02-03. Estimated completion is 2023-12-28.
What interventions are being tested in trial NCT04604210?
The interventions under investigation include: Transcranial magnetic stimulation (PROCEDURE).
Who is sponsoring clinical trial NCT04604210?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.